ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+16.13%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$79.9M
AUM Growth
+$79.9M
(+8.5%)
Cap. Flow
-$3.65M
Cap. Flow
% of AUM
-4.57%
Top 10 Holdings %
Top 10 Hldgs %
57.13%
Holding
44
New
13
Increased
11
Reduced
12
Closed
8
Top Buys
| 1 |
KALA BIO
KALA
|
$1.91M |
| 2 |
Pfizer
PFE
|
$1.89M |
| 3 |
Boston Scientific
BSX
|
$1.87M |
| 4 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
$1.66M |
| 5 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$1.59M |
Top Sells
| 1 |
PTC Therapeutics
PTCT
|
$6.28M |
| 2 |
Quest Diagnostics
DGX
|
$3.15M |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
$2.32M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$2.06M |
| 5 |
NVTA
Invitae Corporation
NVTA
|
$1.97M |
Sector Composition
| 1 | Healthcare | 95.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PTC Therapeutics
PTCT
$3.92B
| $8.64M | 10.81% | 319,444 -232,114 | -42% | -$6.28M |
|
|
OPTN
2
DELISTED
OptiNose
OPTN
| $6.79M | 8.49% | 338,925 +38,307 | +13% | +$767K |
|
3
Centene
CNC
$14.3B
| $5.16M | 6.45% | 48,276 +2,265 | +5% | +$242K |
|
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $4.73M | 5.91% | 31,304 -13,672 | -30% | -$2.06M |
|
|
AERI
5
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $3.78M | 4.73% | 69,676 +29,346 | +73% | +$1.59M |
|
6
UnitedHealth
UNH
$281B
| $3.75M | 4.69% | 17,518 -2,888 | -14% | -$618K |
|
7
Insmed
INSM
$28.8B
| $3.65M | 4.57% | 162,185 +3,908 | +2% | +$88K |
|
|
8
Quest Diagnostics
DGX
$20.3B
| $3.23M | 4.04% | 32,229 -31,381 | -49% | -$3.15M |
|
9
Natera
NTRA
$23.1B
| $3.02M | 3.77% | 325,529 +125,752 | +63% | +$1.17M |
|
10
Amicus Therapeutics
FOLD
$2.34B
| $2.93M | 3.66% | 194,745 -18,668 | -9% | -$281K |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $2.47M | 3.09% | 29,825 +5,030 | +20% | +$417K |
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $2.16M | 2.7% | 29,133 -13,992 | -32% | -$1.04M |
|
13
Heron Therapeutics
HRTX
$207M
| $2.14M | 2.67% | 77,346 -21,835 | -22% | -$603K |
|
|
14
KALA BIO
KALA
$78.8M
| $2.13M | 2.66% | 134,250 +120,746 | +894% | +$1.91M |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $1.94M | 2.42% | 135,974 +74,444 | +121% | +$1.06M |
|
|
16
Pfizer
PFE
$141B
| $1.89M | 2.36% | +53,242 | New | +$1.89M |
|
|
17
Boston Scientific
BSX
$156B
| $1.87M | 2.33% | +68,270 | New | +$1.87M |
|
|
LJPC
18
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $1.66M | 2.08% | +55,864 | New | +$1.66M |
|
19
DURECT Corp
DRRX
$59.6M
| $1.61M | 2.02% | 752,767 -125,430 | -14% | -$268K |
|
20
Inogen
INGN
$216M
| $1.53M | 1.92% | +12,471 | New | +$1.53M |
|
21
Tactile Systems Technology
TCMD
$297M
| $1.35M | 1.69% | 42,460 -629 | -1% | -$20K |
|
|
ARRY
22
DELISTED
Array Biopharma Inc
ARRY
| $1.33M | 1.67% | 81,649 +15,554 | +24% | +$254K |
|
23
Puma Biotechnology
PBYI
$254M
| $1.23M | 1.54% | 18,057 +10,686 | +145% | +$727K |
|
24
Penumbra
PEN
$10.6B
| $1.19M | 1.49% | +10,279 | New | +$1.19M |
|
|
NVRO
25
DELISTED
NEVRO CORP.
NVRO
| $1.13M | 1.42% | 13,087 -10,698 | -45% | -$927K |
|